Teva Pharmaceutical Industries Ltd. $TEVA is Iron Triangle Partners LP's 4th Largest Position

Key Points

• Iron Triangle Partners LP has increased its stake in Teva Pharmaceutical Industries by 0.8%, now owning over 2.2 million shares worth approximately $34.09 million.
• Multiple institutional investors have also increased their holdings in Teva, with some, like Jump Financial LLC, growing their stake by over 172% during the first quarter.
• Analysts have set a range of price targets for Teva's stock, with an average price target of $24.71 and several firms maintaining a 'buy' rating.

Iron Triangle Partners LP raised its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 0.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,217,730 shares of the company's stock after buying an additional 17,694 shares during the quarter. Teva Pharmaceutical Industries accounts for about 5.4% of Iron Triangle Partners LP's portfolio, making the stock its 4th largest position. Iron Triangle Partners LP owned approximately 0.20% of Teva Pharmaceutical Industries worth $34,087,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Tema Etfs LLC lifted its stake in Teva Pharmaceutical Industries by 12.5% in the 1st quarter. Tema Etfs LLC now owns 28,861 shares of the company's stock valued at $444,000 after purchasing an additional 3,199 shares during the last quarter. Trexquant Investment LP lifted its holdings in shares of Teva Pharmaceutical Industries by 114.8% during the first quarter. Trexquant Investment LP now owns 203,909 shares of the company's stock worth $3,134,000 after purchasing an additional 108,986 shares during the period. Lansforsakringar Fondforvaltning AB publ lifted its holdings in Teva Pharmaceutical Industries by 2.2% in the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 250,106 shares of the company's stock valued at $3,844,000 after buying an additional 5,344 shares during the period. Gabelli Funds LLC raised its holdings in shares of Teva Pharmaceutical Industries by 18.4% during the first quarter. Gabelli Funds LLC now owns 435,075 shares of the company's stock valued at $6,687,000 after purchasing an additional 67,575 shares during the period. Finally, Jump Financial LLC increased its position in shares of Teva Pharmaceutical Industries by 172.1% during the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock worth $20,373,000 after acquiring an additional 838,423 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on TEVA. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Finally, UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Stock Performance

TEVA traded up $0.37 during trading on Monday, reaching $18.41. 7,153,308 shares of the company's stock were exchanged, compared to its average volume of 10,852,338. The company's fifty day simple moving average is $16.86 and its 200-day simple moving average is $16.32. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The stock has a market capitalization of $21.11 billion, a P/E ratio of -115.04, a price-to-earnings-growth ratio of 1.09 and a beta of 0.72. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same quarter last year, the business earned $0.61 earnings per share. The company's revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,001 shares of company stock worth $996,958 over the last three months. Company insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.